Skip to main content

Marta Torres Ferrús

Sóc Llicenciada en Medicina per la Universitat Autònoma de Barcelona. Em vaig especialitzar en Neurologia a l'Hospital Universitari Vall d'Hebron on continuo la meva activitat assistencial i investigadora a la Unitat de Cefalees del Servei de Neurologia.

Institutions of which they are part

Main researcher
Headache and Neurological Pain
Vall Hebron Institut de Recerca
Neurology
General Hospital

Marta Torres Ferrús

Institutions of which they are part

Main researcher
Headache and Neurological Pain
Vall Hebron Institut de Recerca
Neurology
General Hospital

Sóc Llicenciada en Medicina per la Universitat Autònoma de Barcelona. Em vaig especialitzar en Neurologia a l'Hospital Universitari Vall d'Hebron on continuo la meva activitat assistencial i investigadora a la Unitat de Cefalees del Servei de Neurologia.

Sóc membre de la "International Headache Society", Grup d'Estudi de Cefalees de la Societat Espanyola de Nerurologia (GECSEN) i de la Societat Catalana de Neurologia.
He rebut múltiples beques per a la realització de projectes de investigació. He publicat articles originals i de revisió i tinc experiència en la realització d'assajos clínics.

Projects

SAMBA: Análisis de biomarcadores de migraña en saliva

IP: Patricia Pozo Rosich
Collaborators: Marta Torres Ferrús, Manuel Quintana Luque
Funding agency: Instituto de Salud Carlos III
Funding: 70785
Reference: PI16/01525
Duration: 01/01/2017 - 31/12/2020

Cefalea i dolor neurològic

IP: Patricia Pozo Rosich
Collaborators: Marta Torres Ferrús, Laia Perez Lasarte
Funding agency: Fundació Institut de Recerca HUVH
Funding: 45000
Reference: PM-CAIXA-2014-01
Duration: 07/01/2015 - 06/01/2017

Related news

Two international studies led by Vall d'Hebron recommend early administration of specific drugs to prevent migraine to achieve a better response to therapy.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

The study, conducted in more than 770 people, concludes that atogepant reduces the frequency of migraine attacks and the need to take medication.

Related professionals

Joaquin Fernandez Doblas

Joaquin Fernandez Doblas

Donation and transplantation of organs, tissues and cells
Read more
Agustín Arasanz Duque

Agustín Arasanz Duque

Tècnic/a Grau Superior
External Strategy Directorate
Read more
Cristina Bernadó Morales

Cristina Bernadó Morales

Predoctoral researcher
Donation and transplantation of organs, tissues and cells
Read more
Joaquin Burgos Cibrian

Joaquin Burgos Cibrian

Main researcher
Infectious Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.